M. Hanafiah, K. Groeger, J. Flaxman, A. Wiersma, and S. , Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence, Hepatology, vol.29, issue.Suppl, pp.1333-1342, 2013.
DOI : 10.1111/j.1478-3231.2008.01927.x

T. Asselah and P. Marcellin, Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir, Liver International, vol.3, issue.Suppl 1, pp.60-68, 2014.
DOI : 10.1056/NEJMoa1208809

L. Hagan, P. Wolpe, and R. Schinazi, Treatment as prevention and cure towards global eradication of hepatitis C virus, Trends in Microbiology, vol.21, issue.12, pp.625-633, 2013.
DOI : 10.1016/j.tim.2013.09.008

J. Ward, The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease, Top Antivir Med, vol.21, pp.15-19, 2013.

G. Pape, T. Gerlach, H. Diepolder, N. Gruner, M. Jung et al., Role of the specific T-cell response for clearance and control of hepatitis C virus, Journal of Viral Hepatitis, vol.6, issue.s1, pp.36-40, 1999.
DOI : 10.1016/S0140-6736(95)91992-9

B. Rehermann, Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells, Nature Medicine, vol.163, issue.7, pp.859-868, 2013.
DOI : 10.1172/JCI40594

J. Pestka, M. Zeisel, E. Bläser, P. Schürmann, B. Bartosch et al., Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C, Proceedings of the National Academy of Sciences, vol.43, issue.6, pp.6025-6030, 2007.
DOI : 10.1002/hep.21191

URL : https://hal.archives-ouvertes.fr/inserm-00395910

S. Raghuraman, H. Park, W. Osburn, E. Winkelstein, B. Edlin et al., Spontaneous Clearance of Chronic Hepatitis C Virus Infection Is Associated With Appearance of Neutralizing Antibodies and Reversal of T-Cell Exhaustion, The Journal of Infectious Diseases, vol.205, issue.5, pp.763-771, 2012.
DOI : 10.1093/infdis/jir835

W. Osburn, A. Snider, B. Wells, R. Latanich, J. Bailey et al., Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses, Hepatology, vol.3, issue.Suppl 7, pp.2140-2151, 2014.
DOI : 10.1186/1753-6561-3-s7-s34

T. Baumert, C. Fauvelle, D. Chen, and G. Lauer, A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing, Journal of Hepatology, vol.61, issue.1, pp.34-44, 2014.
DOI : 10.1016/j.jhep.2014.09.009

URL : http://doi.org/10.1016/j.jhep.2014.09.009

E. Barnes, A. Folgori, S. Capone, L. Swadling, S. Aston et al., Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man, Science Translational Medicine, vol.79, issue.2, pp.115-116, 2012.
DOI : 10.1002/cyto.a.21015

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627207

L. Swadling, S. Capone, R. Antrobus, A. Brown, R. Richardson et al., A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory, Science Translational Medicine, vol.31, issue.2, pp.261-153, 2014.
DOI : 10.1038/nbt.2593

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669853

V. Edwards, A. Tarr, R. Urbanowicz, and J. Ball, The role of neutralizing antibodies in hepatitis C virus infection, Journal of General Virology, vol.93, issue.1, pp.1-19, 2011.
DOI : 10.1099/vir.0.035956-0

J. Ball, A. Tarr, and J. Mckeating, The past, present and future of neutralizing antibodies for hepatitis C virus, Antiviral Research, vol.105, pp.100-111, 2014.
DOI : 10.1016/j.antiviral.2014.02.013

M. Houghton, Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses, Immunological Reviews, vol.436, issue.Suppl., pp.99-108, 2011.
DOI : 10.4049/jimmunol.169.6.3447

J. Meunier, J. Gottwein, M. Houghton, R. Russell, S. Emerson et al., Vaccine-Induced Cross-Genotype Reactive Neutralizing Antibodies Against Hepatitis C Virus, The Journal of Infectious Diseases, vol.204, issue.8, pp.1186-1190, 2011.
DOI : 10.1093/infdis/jir511

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203383

Q. Choo, G. Kuo, R. Ralston, A. Weiner, D. Chien et al., Vaccination of chimpanzees against infection by the hepatitis C virus., Proceedings of the National Academy of Sciences, vol.91, issue.4, pp.1294-1298, 1994.
DOI : 10.1073/pnas.91.4.1294

S. Frey, M. Houghton, S. Coates, S. Abrignani, D. Chien et al., Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults, Vaccine, vol.28, issue.38, pp.6367-6373, 2010.
DOI : 10.1016/j.vaccine.2010.06.084

S. Duvet, L. Cocquerel, A. Pillez, R. Cacan, A. Verbert et al., Hepatitis C Virus Glycoprotein Complex Localization in the Endoplasmic Reticulum Involves a Determinant for Retention and Not Retrieval, Journal of Biological Chemistry, vol.269, issue.48, pp.32088-32095, 1998.
DOI : 10.1083/jcb.122.6.1185

R. Spaete, D. Alexander, M. Rugroden, Q. Choo, K. Berger et al., Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells, Virology, vol.188, issue.2, pp.819-830, 1992.
DOI : 10.1016/0042-6822(92)90537-Y

F. Nevens, T. Roskams, H. Van-vlierberghe, Y. Horsmans, D. Sprengers et al., A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C, Hepatology, vol.31, issue.5, pp.1289-1296, 2003.
DOI : 10.1053/jhep.2003.50474

G. Leroux-roels, A. Batens, I. Desombere, B. Van-den-steen, V. Stichele et al., Immunogenicity and Tolerability of Intradermal Administration of an HCV E1-Based Vaccine Candidate in Healthy Volunteers and Patients with Resolved or Ongoing Chronic HCV Infection, Human Vaccines, vol.1, issue.2, pp.61-65, 2005.
DOI : 10.4161/hv.1.2.1554

I. Sominskaya, E. Alekseeva, D. Skrastina, V. Mokhonov, E. Starodubova et al., Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene, Molecular Immunology, vol.43, issue.12, pp.1941-1952, 2006.
DOI : 10.1016/j.molimm.2005.11.018

R. Patient, C. Hourioux, P. Vaudin, J. Pagès, and P. Roingeard, Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies, New Biotechnology, vol.25, issue.4, pp.226-234, 2009.
DOI : 10.1016/j.nbt.2009.01.001

URL : https://hal.archives-ouvertes.fr/inserm-00380276

E. Beaumont, R. Patient, C. Hourioux, I. Dimier-poisson, and P. Roingeard, Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine, Hepatology, vol.8, issue.Suppl 1, pp.1303-1313, 2013.
DOI : 10.1016/S1473-3099(08)70126-9

URL : https://hal.archives-ouvertes.fr/inserm-00812948

H. Netter, T. Macnaughton, W. Woo, R. Tindle, and E. Gowans, Antigenicity and Immunogenicity of Novel Chimeric Hepatitis B Surface Antigen Particles with Exposed Hepatitis C Virus Epitopes, Journal of Virology, vol.75, issue.5, pp.2130-2141, 2015.
DOI : 10.1128/JVI.75.5.2130-2141.2001

E. Beaumont and P. Roingeard, Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine, Vaccine, vol.33, issue.8, pp.973-976, 2015.
DOI : 10.1016/j.vaccine.2015.01.007

URL : https://hal.archives-ouvertes.fr/inserm-01575077

E. Blanchard, D. Brand, S. Trassard, A. Goudeau, and P. Roingeard, Hepatitis C Virus-Like Particle Morphogenesis, Journal of Virology, vol.76, issue.8, pp.4073-4079, 2002.
DOI : 10.1128/JVI.76.8.4073-4079.2002

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC136094

E. Santolini, G. Migliaccio, L. Monica, and N. , Biosynthesis and biochemical properties of the hepatitis C virus core protein, J Virol, vol.68, pp.3631-3641, 1994.

L. Cocquerel, C. Wychowski, F. Minner, F. Penin, and J. Dubuisson, Charged Residues in the Transmembrane Domains of Hepatitis C Virus Glycoproteins Play a Major Role in the Processing, Subcellular Localization, and Assembly of These Envelope Proteins, Journal of Virology, vol.74, issue.8, pp.3623-3633, 2000.
DOI : 10.1128/JVI.74.8.3623-3633.2000

URL : https://hal.archives-ouvertes.fr/hal-00313712

T. Wakita, T. Pietschmann, T. Kato, T. Date, M. Miyamoto et al., Production of infectious hepatitis C virus in tissue culture from a cloned viral genome, Nature Medicine, vol.37, issue.7, pp.791-796, 2005.
DOI : 10.1002/jmv.10297

J. Gottwein, T. Scheel, A. Hoegh, J. Lademann, J. Eugen-olsen et al., Robust Hepatitis C Genotype 3a Cell Culture Releasing Adapted Intergenotypic 3a/2a (S52/JFH1) Viruses, Gastroenterology, vol.133, issue.5, pp.1614-1626, 2007.
DOI : 10.1053/j.gastro.2007.08.005

T. Scheel, J. Gottwein, T. Jensen, J. Prentoe, A. Hoegh et al., Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization, Proceedings of the National Academy of Sciences, vol.165, issue.3, pp.997-1002, 2008.
DOI : 10.1093/infdis/165.3.438

J. Gottwein, T. Scheel, T. Jensen, J. Lademann, J. Prentoe et al., Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs, Hepatology, vol.46, issue.2, pp.364-377, 2009.
DOI : 10.1002/hep.21994

F. Miller and L. Abu-raddad, Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt, Proceedings of the National Academy of Sciences, vol.82, issue.5-6, pp.14757-14762, 2010.
DOI : 10.1053/jhep.2001.20797

Z. Keck, V. Sung, S. Perkins, R. J. Paul, S. Liang et al., Human Monoclonal Antibody to Hepatitis C Virus E1 Glycoprotein That Blocks Virus Attachment and Viral Infectivity, Journal of Virology, vol.78, issue.13, pp.7257-7263, 2004.
DOI : 10.1128/JVI.78.13.7257-7263.2004

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC421663

Z. Keck, T. Li, J. Xia, M. Gal-tanamy, O. Olson et al., Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies, Journal of Virology, vol.82, issue.12, pp.6061-6066, 2008.
DOI : 10.1128/JVI.02475-07

J. Meunier, R. Russell, V. Goossens, S. Priem, H. Walter et al., Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus, Journal of Virology, vol.82, issue.2, pp.966-973, 2008.
DOI : 10.1128/JVI.01872-07

E. Giang, M. Dorner, J. Prentoe, M. Dreux, M. Evans et al., Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus, Proceedings of the National Academy of Sciences, vol.2, issue.4, pp.6205-6210, 2012.
DOI : 10.1162/153535003322750637

H. Dahari, S. Feinstone, and M. Major, Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural Proteins, Gastroenterology, vol.139, issue.3, pp.965-974, 2010.
DOI : 10.1053/j.gastro.2010.05.077

G. Leroux-roels, E. Depla, F. Hulstaert, L. Tobback, S. Dincq et al., A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers, Vaccine, vol.22, issue.23-24, pp.3080-3086, 2004.
DOI : 10.1016/j.vaccine.2004.02.002

P. Garrone, A. Fluckiger, P. Mangeot, E. Gauthier, P. Dupeyrot-lacas et al., A Prime-Boost Strategy Using Virus-Like Particles Pseudotyped for HCV Proteins Triggers Broadly Neutralizing Antibodies in Macaques, Science Translational Medicine, vol.71, issue.1, p.21813755, 2011.
DOI : 10.1007/978-1-59745-394-3_32

G. Leroux-roels, C. Esquivel, R. Deleys, L. Stuyver, A. Elewaut et al., Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alfa, Hepatology, vol.192, issue.1, pp.8-16, 1996.
DOI : 10.1006/bbrc.1993.1462

B. Verstrepen, E. Depla, C. Rollier, G. Mares, J. Drexhage et al., Clearance of Genotype 1b Hepatitis C Virus in Chimpanzees in the Presence of Vaccine-Induced E1-Neutralizing Antibodies, The Journal of Infectious Diseases, vol.204, issue.6, pp.837-844, 2011.
DOI : 10.1093/infdis/jir423

Z. Stamataki, S. Coates, M. Evans, M. Wininger, K. Crawford et al., Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies, Vaccine, vol.25, issue.45, pp.7773-7784, 2007.
DOI : 10.1016/j.vaccine.2007.08.053

T. Ruwona, E. Giang, T. Nieusma, and M. Law, Fine Mapping of Murine Antibody Responses to Immunization with a Novel Soluble Form of Hepatitis C Virus Envelope Glycoprotein Complex, Journal of Virology, vol.88, issue.18, pp.10459-10471, 2014.
DOI : 10.1128/JVI.01584-14

R. Valle, J. De-la-fuente, C. Turner, M. Springfeld, C. Apte-sengupta et al., Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster, Journal of Virology, vol.86, issue.21, pp.11558-11566, 2012.
DOI : 10.1128/JVI.01776-12

G. Vieyres, X. Thomas, V. Descamps, G. Duverlie, A. Patel et al., Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C Virus, Journal of Virology, vol.84, issue.19, p.20668082, 2010.
DOI : 10.1128/JVI.01180-10